Abstract 370P
Background
Immune checkpoint inhibitors (ICI) have proven efficacy in R/M HNSCC. In LMICs, <5% of patients have access to ICI at approved doses. We assessed the efficacy of low dose ICI in locally advanced/inoperable HNSCC.
Methods
We conducted retrospective analysis of patients with locally advanced/inoperable HNSCC who underwent induction chemotherapy with low dose nivolumab. Eligible doses of nivolumab were <3mg/kg q2w with chemotherapy backbone of TPX or TP+/- OMCT. The principal outcomes were conversion to radical therapy, ORR, PFS and OS.
Results
We included 111 patients, 78.4% males with median age 48. Primary sites- oral cavity(71.2%), hypopharynx(11.7%), oropharynx(9%) and larynx(8.1%) mainly stage IVA/IVB. TPX/TP was used in 95.4%. Nivolumab 20/40/100 mg all 2/3/4 weeks were the doses and intervals. The harmonized median dose of nivolumab was 0.51 mg/kg q2w (median 3 doses). Response assessment was available for 92 of 111 patients- CR in 7 (6.3%), PR in 65(58.6%), SD in 12(10.8%), PD in 8(7.2%). ORR was 78.2% in those assessed. 25(31.6%) oral cavity tumours became resectable following induction, of whom, 8(32%) had pCR. 60% of oropharyngeal, 69% of hypopharynx and 77.8% of larynx primary site underwent radical RT/CRT after induction. Median PFS is 18.6 months. PFS and OS at 1 year were 64.6% and 82.6%. Median PFS not reached in the cohort with pCR/rCR and 18 months in the group without(p 0.03). No recurrence/death observed thus far in those with pCR. At nivolumab doses <0.6mg/kg, median PFS was significantly lower (13 months vs NR; p 0.04). The retrospective design introduces potential confounders. Grade 3/4 AEs were neutropenia (14.4%), CINV (2.7%), anemia(2.7%), mucositis(1.8%) and febrile neutropenia(1%); Any grade hyponatremia(14%), hypothyroidism(5%).
Conclusions
Low-dose ICI with induction chemotherapy demonstrated promising ORR and conversion to radical therapy. Survival, although immature, appears favourable, especially for patients with pCR/rCR. Doses of nivolumab < 0.6mg/kg may compromise survival. Low-dose (1/6th of standard dose) regimens could enhance ICI access in LMICs due to significantly reduced costs and merit investigation in randomised trials to confirm our findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institutional Review Board (Ethics committee) of the Christian Medical College Vellor.
Funding
Has not received any fundin.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
613P - Differences in the interactions with pharmaceutical companies between medical oncologists and infectious diseases physicians
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
614P - The role of PD-L1 expression in prognosis of osteosarcoma patients: A systematic review and meta-analysis
Presenter: Alexander Purnomo
Session: Poster Display
Resources:
Abstract
615P - Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
Presenter: Qiyuan Bao
Session: Poster Display
Resources:
Abstract
616P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Paula Franco
Session: Poster Display
Resources:
Abstract
617P - The risk of acute myeloid leukaemia in patients with Ewing's sarcoma and trend analysis: A SEER-based study 2000-2020
Presenter: Mohamed Abdalla
Session: Poster Display
Resources:
Abstract
618P - Adult renal Ewing’s sarcoma/primitive neuroectodermal tumor: A 20-year retrospective review of molecular histopathological profiles, and clinical outcomes
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
619P - Single-cell and bulk RNA-seq analyses decode the renal microenvironment induced by polystyrene microplastics in mice receiving high-fat diet
Presenter: Wangrui Liu
Session: Poster Display
Resources:
Abstract
620P - A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancer
Presenter: Dongyu Li
Session: Poster Display
Resources:
Abstract
621P - Effective identification of primary liver cancer from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers: Marker discovery, phase I pilot, and phase II clinical validation
Presenter: Tian Yang
Session: Poster Display
Resources:
Abstract
622P - A prognostic and immune infiltration analysis of CCL26 in pan-cancer
Presenter: Mengyue Li
Session: Poster Display
Resources:
Abstract